Brought to you by 
Alnylam closes $2mm Series A round
16 Aug 2002
Executive Summary
Alnylam Pharmaceuticals (cancer, inflammation, and infectious disease drug development) closed a $2mm Series A private placement of stock to Cardinal Partners, Cardinal Venture Capital, and Polaris Venture Partners.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alnylam closes $2mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice